Shares of Australian specialty pharma firm Mayne Pharma Group (ASX: MYX) closed up 9.2% at A$3.68 today, after it released full-year fiscal 2023 financials, showing that reported revenues were A$183.6 million (US$118.5 million), up 17% on FY 2022.
International revenue increased 19% to A$64.7 million, largely due to increased contract manufacturing in second half FY 2023. During that period, the international segment showed significant improvement in direct contribution of A$4.1 million (versus A$2.8 million).
Reported gross profit was also up 17% at A$83.5 million, with net loss after tax coming in at A$317.4 million, compared with A$220.1 million the previous year
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze